Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-01
1997-09-23
Davis, Zinna Northington
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546147, C07D21514, A61K 3147
Patent
active
056705166
ABSTRACT:
This invention provides novel decahydroisoquinoline compounds which are useful as excitatory amino acid receptor antagonists and in the treatment of neurological disorders. This invention also provides synthetic methods for preparing decahydroisoquinolines, as well as, novel intermediates in the synthesis thereof.
REFERENCES:
patent: 4902695 (1990-02-01), Ornstein
patent: 5071859 (1991-12-01), Knudsen et al.
Sheardown et al., "2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo (F) quinoxaline: A Neuroprotectant for Cerebral Ischemia", Science, 247, 571-574 (1990).
Buchan et al., "Delayed AMPA receptor blockade reduces cerebral infarction induced by focal ischemia", Neuroreport, 2, 473-476 (1991).
LePeillet et al., "The non-NMDA antagonists, NBQX and GYKI 52466, protect against cortical and straital cell loss following transient global ischaemia in the rat", Brain Research, 571, 115-120 (1992).
Ornstein et al., "Synthesis of 6-Oxodecahydroisoquinoline-3-carboxylates. Useful Intermediates for the Preparation of Conformationally Defined Excitatory Amino Acid Antagonists", J. Org. Chem., 56, 4388-4392 (1991).
Jacques et al., Enantiomers, Racemates, and Resolutions, 253-259, John Wiley and Sons, N.Y., (1981).
Ornstein et al., "6-Substituted Decahydroisoquinoline-3-carboxylic Acids as Potent and Selective Conformationally Constrained NMDA Receptor Antagonists", J. Med. Chem., 35, 3547-3560 (1992).
J. Med. Chem., 36(14), 2046-2048 (1993).
J. Med. Chem., 39(11), 2219-2231 (1996).
J. Med. Chem., 39(11), 2232-2244 (1996).
Arnold M. Brian
Augenstein Nancy K.
Lunn William H. W.
Ornstein Paul L.
Schoepp Darryle D.
Davis Zinna Northington
Eli Lilly and Company
Hay Martin A.
Leeds James P.
LandOfFree
Excitatory amino acid receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Excitatory amino acid receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Excitatory amino acid receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1938768